Payment overview · 2025
General Payments
$1,042.04
65 reported records · 18 companies
Healthcare provider profile · identity verified
Troy E Hampton, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · LANCASTER, OH · NPI 1275536377
Verified facts
What the public records show
CMS Open Payments records show Troy E Hampton, D.O. received $1,042.04 in general payments during 2025 across 65 reported records.
PFIZER INC. accounted for 19.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Kerendia, Linzess, Mounjaro, Nurtec Odt, Ozempic, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Kerendia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $198.50 | 19.1% | 13 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $142.10 | 13.6% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $135.74 | 13.0% | 15 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $90.14 | 8.7% | 4 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $70.76 | 6.8% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $55.42 | 5.3% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $44.42 | 4.3% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $42.56 | 4.1% | 3 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $42.20 | 4.0% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $35.22 | 3.4% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $32.73 | 3.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $32.22 | 3.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $29.61 | 2.8% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.99 | 2.4% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $19.02 | 1.8% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $18.49 | 1.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.33 | 1.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $13.59 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $997.04 | 64 |
| Education | $45.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $168.24 | 11 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $142.10 | 7 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $93.90 | 8 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $74.34 | 3 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $70.76 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $55.42 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $51.68 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $45.14 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $45.14 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $44.42 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $42.56 | 3 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $42.20 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $41.59 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $41.59 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $35.22 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $32.73 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $32.22 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $30.26 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $30.26 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $29.61 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $24.99 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $24.84 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $24.84 | 3 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $19.02 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $18.49 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $17.63 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.88 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.33 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $13.59 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $13.38 | 1 | 2025 |
Source payment records
|
|||||
| TRUMENBA Normalized: trumenba |
Biological | PFIZER INC. | $13.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 86 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 49 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
53 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
49 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
86 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 262 | 72 |
| Levothyroxine Sodium | Levothyroxine Sodium | 244 | 76 |
| Omeprazole | Omeprazole | 168 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 158 | 42 |
| Amlodipine Besylate | Amlodipine Besylate | 156 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 155 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 139 | 41 |
| Alprazolam | Alprazolam | 139 | 14 |
| Tramadol Hcl | Tramadol Hcl | 135 | 26 |
| Montelukast Sodium | Montelukast Sodium | 134 | 36 |
| Sertraline Hcl | Sertraline Hcl | 132 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 129 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 128 | 37 |
| Gabapentin | Gabapentin | 119 | 24 |
| Furosemide | Furosemide | 107 | 27 |
| Pioglitazone Hcl | Pioglitazone Hcl | 104 | 28 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 101 | 15 |
| Irbesartan | Irbesartan | 98 | 29 |
| Lisinopril | Lisinopril | 98 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 95 | 20 |
| Trazodone Hcl | Trazodone Hcl | 91 | 20 |
| Eliquis | Apixaban | 86 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 85 | 25 |
| Baclofen | Baclofen | 84 | 18 |
| Prednisone | Prednisone | 82 | 43 |
| Lorazepam | Lorazepam | 80 | 20 |
| Carvedilol | Carvedilol | 79 | 22 |
| Potassium Chloride | Potassium Chloride | 77 | 23 |
| Buspirone Hcl | Buspirone Hcl | 68 | 14 |
| Glipizide Er | Glipizide | 68 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 65 | 15 |
| Tresiba Flextouch U-200 | Insulin Degludec | 65 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 61 | 25 |
| Memantine Hcl | Memantine Hcl | 57 | 14 |
| Metformin Hcl Er | Metformin Hcl | 55 | 20 |
| Finasteride | Finasteride | 53 | 16 |
| Synthroid | Levothyroxine Sodium | 53 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 50 | 14 |
| Allopurinol | Allopurinol | 49 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 49 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 49 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 49 | suppressed |
| Ozempic | Semaglutide | 49 | 12 |
| Meloxicam | Meloxicam | 47 | 15 |
| Famotidine | Famotidine | 46 | 14 |
| Losartan Potassium | Losartan Potassium | 44 | 13 |
| Metformin Hcl | Metformin Hcl | 44 | 11 |
| Clonazepam | Clonazepam | 43 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 41 | 11 |
| Glyxambi | Empagliflozin/Linagliptin | 41 | suppressed |
| Celecoxib | Celecoxib | 40 | 13 |
| Mirtazapine | Mirtazapine | 40 | suppressed |
| Repatha Sureclick | Evolocumab | 40 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 40 | 14 |
| Bupropion Xl | Bupropion Hcl | 39 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 37 | 12 |
| Ezetimibe | Ezetimibe | 36 | suppressed |
| Kerendia | Finerenone | 35 | suppressed |
| Simvastatin | Simvastatin | 35 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 35 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 34 | suppressed |
| Ketoconazole | Ketoconazole | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 32 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 31 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 31 | suppressed |
| Glimepiride | Glimepiride | 30 | suppressed |
| Nifedipine Er | Nifedipine | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 29 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 16 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 15 |
| Valsartan | Valsartan | 27 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 26 | suppressed |
| Azithromycin | Azithromycin | 26 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Creon | Lipase/Protease/Amylase | 26 | suppressed |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Mupirocin | Mupirocin | 25 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 23 | suppressed |
| Jardiance | Empagliflozin | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | 12 |
| Colchicine | Colchicine | 22 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Rybelsus | Semaglutide | 22 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 12 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Fluconazole | Fluconazole | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 20 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Klor-Con M10 | Potassium Chloride | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Nadolol | Nadolol | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Cholestyramine Light | Cholestyramine | 14 | suppressed |
| Epinephrine | Epinephrine | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 11 |
| Clonidine | Clonidine | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Budesonide | Budesonide | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Dulera | Mometasone/Formoterol | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,042.04 · 65 records | PFIZER INC. | ABRYSVO, ACCRUFER, AIRSUPRA, CAPLYTA, COMIRNATY, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FREESTYLE LIBRE 3, GVOKE HYPOPEN, Kerendia, Korlym, LEQVIO, LINZESS, MOUNJARO, NURTEC ODT, Ozempic, PENBRAYA, PREVNAR 20, Prolastin-C Liquid, QULIPTA, REXULTI, TRUMENBA, UBRELVY, VIBERZI, VOQUEZNA, VRAYLAR, Veozah, ZAVZPRET, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error